504
Participants
Start Date
December 11, 2015
Primary Completion Date
September 15, 2017
Study Completion Date
November 24, 2023
Nivolumab
Docetaxel
Local Institution - 0008, Hangzhou
Local Institution - 0031, Beijing
Local Institution - 0049, Hong Kong
Local Institution - 0051, Beijing
Local Institution - 0029, Beijing
Local Institution - 0007, Beijing
Local Institution - 0032, Beijing
Local Institution - 0026, Beijing
Local Institution - 0052, Moscow
Local Institution - 0048, Singapore
Local Institution - 0046, Moscow
Local Institution - 0006, Changchun
Local Institution - 0022, Changchun
Local Institution - 0042, Saint Petersburg
Local Institution - 0040, Saint Petersburg
Local Institution - 0041, Saint Petersburg
Local Institution - 0014, Shanghai
Local Institution - 0028, Shanghai
Local Institution - 0017, Shanghai
Local Institution - 0025, Shanghai
Local Institution - 0034, Nanjing
Local Institution - 0037, Singapore
Local Institution - 0009, Hangzhou
Local Institution - 0010, Hangzhou
Local Institution - 0015, Fuzhou
Local Institution - 0020, Chongqing
Local Institution - 0023, Changsha
Local Institution - 0012, Changsha
Local Institution - 0024, Zhengzhou
Local Institution - 0039, Chelyabinsk
Local Institution - 0003, Guangzhou
Local Institution - 0002, Guangzhou
Local Institution - 0011, Chengdu
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY